SLFN12 and acute myeloid leukemia: However, our experiments suggest that velcrin treatment of SLFN12-expressing AML cells results in complex formation between SLFN12 and PDE3 (Fig. 3H and I), leading to SLFN12 stabilization (Fig. 3A–D) and induction anti-leukemogenic effects (Fig. 3E and F).